Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Genocury Biotech announces positive results from noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma
Genocury Biotech announces positive results from noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma
Read more
Report
Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability.
Read more
Report
Genocury Biotech Announces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
/PRNewswire/ -- Genocury Biotech today revealed groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large...
Read more
Report